doi:10.3969/j.issn.1673-8640.2020.01.020

Abstract

CLC Number:

R446.1

Figures/Tables 5

References 13

[1]	卫蓓文,唐暐,彭奕冰,等. 全相合异基因造血干细胞移植后免疫重建的研究[J]. 检验医学,2014,29(9):925-929.
[2]	ROMERO S,SOLVES P,LANCHARRO A,et al.Passenger lymphocyte syndrome in liver transplant recipient:a description of 12 cases[J]. Blood Transfus,2015,13(3):423-428.
[3]	SKEATE R,SINGH C,COOLEY S,et al.Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products[J]. Transfusion,2013,53:419-423.
[4]	MONFORT M,HONORÉ P,GOTHOT A,et al.Simultaneous passenger lymphocyte syndrome and multiple alloimmunization against donor’s blood group antigens after liver transplantation[J]. Vox Sang,2015,109(1):86-90.
[5]	PECK J R,ELKHAMMAS E A,LI F,et al.Passenger lymphocyte syndrome:a forgotten cause of postliver transplant jaundice and anemia[J]. Exp Clin Transplant,2015,13(2):200-202.
[6]	PETZ L D.Immune hemolysis associated with transplantation[J]. Semin Hematol,2005,42(3):145-155.
[7]	DE LA RUBIA J,ARRIAGA F,ANDREU R,et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation:is ABO incompatibility a predisposing factor?[J]. Transfusion,2001,41(1):106-110.
[8]	SOKOL R J,STAMPS R,BOOKER D J,et al.Posttransplant immune-mediated hemolysis[J]. Transfusion,2002,42(2):198-204.
[9]	HEERWAGEN C,SCHUSTER M,BORNSCHEURER A,et al.Rapid exchange of large numbers of donor- and host leukocytes after human liver transplantation[J]. Transpl Int,2001,14(4):240-247.
[10]	明英姿,庄权,成柯,等. 肝移植术后过客淋巴细胞综合征的发病机制和研究进展[J]. 器官移植,2017,8(4):316-319.
[11]	王文婷,张保萍,刘丽娜,等. 过客淋巴细胞引起ABO非同型肝移植患者术后发生溶血反应1例[J]. 中国输血杂志,2016,29(2):207-209.
[12]	TSUJIMURA K,ISHIDA H,TANABE K.Is efficacy of the anti-cd20 antibody rituximab preventing hemolysis due to passenger lymphocyte syndrome?[J]. Ther Apher Dial,2017,21(1):22-25.
[13]	吴迪,朱志军,张雅敏,等. 皮质激素联合洗涤红细胞输注治疗ABO血型不合肝移植后过客淋巴细胞综合症一例[J]. 中华器官移植杂志,2013,34(7):438-439.

术后时间	血红蛋白/（g/L）	总胆红素/（μmol/L）	间接胆红素/（μmol/L）	直接胆红素/（μmol/L）	抗A滴度
第8天	72	34.14	28.56	5.58	—
第10天	70	38.75	34.99	3.76	—
第12天	67	56.97	49.14	7.83	—
第14天	46	59.32	50.82	8.50	16
第16天	62	33.22	25.90	7.32	8
第19天	75	31.50	15.95	15.55	2
第21天	84	29.89	19.40	10.49	1

术后时间	血红蛋白/（g/L）	总胆红素/（μmol/L）	间接胆红素/（μmol/L）	直接胆红素/（μmol/L）	抗A滴度
第8天	72	34.14	28.56	5.58	—
第10天	70	38.75	34.99	3.76	—
第12天	67	56.97	49.14	7.83	—
第14天	46	59.32	50.82	8.50	16
第16天	62	33.22	25.90	7.32	8
第19天	75	31.50	15.95	15.55	2
第21天	84	29.89	19.40	10.49	1

方法	抗A	抗B	抗D	A1c	自身c
室温立即离心	4+	4+	4+	1+w	1+w
室温孵育后离心	4+	4+	4+	1+w	1+w
4 ℃孵育后离心	—	—	—	1+s	2+
37 ℃孵育后离心	4+	4+	4+	1+	1+

方法	抗A	抗B	抗D	A1c	自身c
室温立即离心	4+	4+	4+	1+w	1+w
室温孵育后离心	4+	4+	4+	1+w	1+w
4 ℃孵育后离心	—	—	—	1+s	2+
37 ℃孵育后离心	4+	4+	4+	1+	1+

检测时间	Ⅰ	Ⅱ	Ⅲ	自身对照
术前
试管法	0	0	0	0
卡式法	0	0	0	0
术后第14天
试管法	0	0	0	1+
卡式法	0	0	0	3+

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 13

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.